Radiotherapy Combined With Endostatin and Capecitabine for NPC

This study tests a treatment combining radiation therapy with two drugs — endostatin (a protein that blocks blood vessel growth in tumors) and capecitabine (an oral chemotherapy) — for patients with locally advanced nasopharyngeal carcinoma (NPC), a type of head and neck cancer behind the nose. The aim is to see whether adding endostatin improves treatment outcomes. **You may be eligible if...** - You have been diagnosed with non-keratinizing nasopharyngeal carcinoma confirmed by biopsy - Your cancer is locally advanced (staged T3-4, with certain lymph node involvement, no distant spread) - You have not received prior treatment for this cancer - Your blood counts, liver, kidney, and performance status meet the required levels (Karnofsky score above 70) **You may NOT be eligible if...** - Your cancer has spread to distant organs - You have already received chemotherapy or radiation for this cancer - You have severe organ dysfunction (liver, kidney, or bone marrow problems) - You are pregnant or breastfeeding - You are allergic to any of the study drugs Talk to your doctor to see if this trial is right for you.